Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Numerous trials have investigated the role of the long-chain omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the prevention of cardiovascular events, with renewed interest sparked by recent findings that omega-3 PUFAs are substrates for lipid mediators of the resolution of inflammation [1, 2]. Whereas some meta-analyses indicated no risk reduction for MI by omega-3 PUFA [3], the most recent revealed a significantly 8% lower risk of MI, with higher doses of omega-3 PUFA conferring greatest protection [4]. Since then, the results of the STRENGTH trial were reported and showed that high-dose omega-3 PUFA (4 g, of which 2.2 g EPA and 0.8 g DHA) supplementation had no significant effects on either the composite primary endpoint or non-fatal MI [5]. Therefore, we aimed to update existing meta-analyses [3, 4] with subsequently published trials to determine the association between EPA and DHA and their dosages with MI risk. We included all trials from the meta-analysis by Aung et al. [3] along with five subsequently published trials, namely, REDUCE-IT, VITAL, ASCEND (references in [6]), OMEMI [7], and STRENGTH [5]. The study pool consisted of randomized trials with minimally 500 patients and a follow-up period of at least one year that analyzed the association between omega-3 PUFA supplementation and vascular events. In total, 15 relevant trials were included. While both fatal and non-fatal MI outcomes were analyzed, in this report, we present analyses on nonfatal MI risk since more non-fatal MI events were recorded in the included trials, making this approach more statistically powerful. For each trial, Peto odds ratio was calculated to determine effect sizes. A meta-analytic scatterplot was created to visualize the risk of MI in each trial based on the dosage for EPA and DHA, respectively, using a randomeffects model. A meta-analytic regression line was fitted in the scatterplot to determine the risk trend and slope for the two omega-3 PUFAs. All statistical calculations were done using the suite of commands, “meta,” in Stata version 16 (StataCorp. 2019. Release 16. College Station, TX: StataCorp LLC). A two-sided alpha value of 0.05 was used to determine statistical significance. Despite the non-significant effects of the latest trial [5], omega-3 supplementation was associated with a statistically significant lower odds of nonfatal MI (odds ratio 0.91; 95% CI 0.83–0.99) in the metaanalysis of 15 studies, with moderate heterogeneity between estimates from individual trials (I2 = 44%) (Fig. 1A). A significant dose-dependent risk reduction of non-fatal MI was observed for EPA (Fig. 1B). While DHA was significantly associated with a lower risk of non-fatal MI at low doses, the risk reduction lost significance at higher doses (Fig. 1B). In a bivariate meta-regression analysis, with EPA and DHA as covariates, EPA achieved a significant non-fatal MI risk reduction (P = 0.048; z = -1.97), while the effect of DHA was non-significant (P = 0.477; z = 0.71). In a sensitivity analysis including only double-blind trials, a univariate meta-regression revealed significant (P = 0.048; z = -1.98) beneficial risk reduction properties of EPA. Together, these findings point to a dose-dependent risk reduction of non-fatal MI with increasing EPA dosage, regardless of DHA intake. In order to account for these differential effects, one could look at * Philip Sarajlic philip.sarajlic@ki.se
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Systematic reviews of the aforementioned studies with meta-analyses and meta-regressions show a dose-dependent association between omega-3 fatty acids’ titration and cardiovascular events [104, 106, 109–111].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341 · cited 2×
“Numerous trials have investigated the role of the long-chain omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the prevention of cardiovascular events, with renewed interest sparked by recent findings that omega-3 PUFAs are substrates for lipid mediators of the…”
BackgroundSelf-citationNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632
Hu, Y., Hu, F. B., & Manson, J. E. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013543 · Cited by 388
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction
Kalstad, A. A., Myhre, P. L., Laake, K., Tveit, S. H., Schmidt, E. B., Smith, P., Nilsen, D. W. T., Tveit, A., Fagerland, M. W., Solheim, S., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052209 · Cited by 311
Laguna-Fernandez, A., Checa, A., Carracedo, M., Artiach, G., Petri, M. H., Baumgartner, R., Forteza, M. J., Jiang, X., Andonova, T., Walker, M. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032801 · Cited by 141
Self-citationOmega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation
Bäck, M., & Hansson, G. K. (2019) · The FASEB Journal · doi:10.1096/fj.201802445r · Cited by 104
Self-citation
Research works printed but not linked: 1
- 1. Bäck M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT. Inflam- mation and its resolution in atherosclerosis: mediators and thera- peutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406.
Cited by
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Doi, T., Langsted, A., & Nordestgaard, B. G. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab555 · Cited by 87
“99).(32) Furthermore, in meta-regression, a dose-dependent risk reduction”
BackgroundChong, S. Y., Wang, X., van Bloois, L., Huang, C., Sayed, N., Zhang, S., Ting, H. J., Nair, V., Lin, Y., Lou, C. K. L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.035 · Cited by 51
Serhan, C. N., Bäck, M., Chiurchiù, V., Hersberger, M., Mittendorfer, B., Calder, P. C., Waitzberg, D. L., Stoppe, C., Kłęk, S., Martindale, R. G., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400619r · Cited by 56
“4 Focussing on increased availability of substrates such as EPA and DHA, it is notable that endogenous production of SPMs is favored by the higher EPA and DHA status brought about by increased supply of these fatty acids.”
BackgroundInfluentialSelf-citationDrenjančević, I., & Pitha, J. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042104 · Cited by 236
Metadata
- Authors
- Sarajlic, P., Artiach, G., Larsson, S. C., & Bäck, M.
- Affiliations
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Uppsala University (SE)
- Corresponding author
- Sarajlic, Philip
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2021-06-08
- Volume
- 35
- Issue
- 5
- Pages
- 1079-1081
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- PMC
- PMC8452549
- OpenAlex
- W3168744603
- Semantic Scholar
- 1b2d893d8df878d95b6a097c3da195743fad6ea0
- Cited by
- 19
- References
- 8
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1 · 2023: 8 · 2022: 4 · 2021: 1
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Funders
- Clinical Scientist Training Program
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- eicosapentaenoic acid, omega-3 fatty acids, myocardial infarction, dose-response relationship, risk mitigation, statin therapy
- MeSH terms
- Docosahexaenoic Acids, Dose-Response Relationship, Drug, Humans, Myocardial Infarction, Eicosapentaenoic Acid, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial. https://app.cochat.ai/papers/10.1007/s10557-021-07212-z
- The paper
- Sarajlic, P., Artiach, G., Larsson, S. C., & Bäck, M. (2021). Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-021-07212-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.